About DARA Biosciences (NASDAQ:DARA)
DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.
Industry, Sector and Symbol
Industry Specialty & Advanced Pharmaceuticals
Trailing P/E Ratio-1.69230769230769
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-145.61%
Return on Assets-100.38%
DARA Biosciences (NASDAQ:DARA) Frequently Asked Questions
What is DARA Biosciences' stock symbol?
DARA Biosciences trades on the NASDAQ under the ticker symbol "DARA."
How were DARA Biosciences' earnings last quarter?
DARA Biosciences Inc (NASDAQ:DARA) announced its earnings results on Monday, November, 2nd. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.14). The specialty pharmaceutical company had revenue of $1.18 million for the quarter, compared to analyst estimates of $0.83 million. DARA Biosciences had a negative return on equity of 145.61% and a negative net margin of 228.42%. View DARA Biosciences' Earnings History.
Who are some of DARA Biosciences' key competitors?
Some companies that are related to DARA Biosciences include Actinium Pharmaceuticals (ATNM), Can Fite Biopharma (CANF), Surgical Innovations (SUN), ReNeuron Group (RENE), Avacta Group (AVCT), Uroplasty (UPI), Repros Therapeutics (RPRX), WaferGen Bio-systems (WGBS), Akers Biosciences (AKR), Macrocure (MCUR), AmpliPhi Biosciences (APHB), Cambridge Cognition (COG), Synairgen (SNG), Shield Therapeutics (STX), CorMedix (CRMD), ValiRx (VAL), Vernalis (VER) and Midatech Pharma (MTPH).
Has DARA Biosciences been receiving favorable news coverage?
Press coverage about DARA stock has been trending positive on Thursday, according to Accern Sentiment. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DARA Biosciences earned a daily sentiment score of 0.27 on Accern's scale. They also gave media headlines about the specialty pharmaceutical company an impact score of 44.55 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of DARA Biosciences?
Shares of DARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DARA Biosciences' stock price today?
One share of DARA stock can currently be purchased for approximately $0.88.
How big of a company is DARA Biosciences?
DARA Biosciences has a market capitalization of $17.38 million.
How can I contact DARA Biosciences?
DARA Biosciences' mailing address is 8601 Six Forks Rd Ste 160, RALEIGH, NC 27615-2965, United States. The specialty pharmaceutical company can be reached via phone at +1-816-9147027.
MarketBeat Community Rating for DARA Biosciences (DARA)MarketBeat's community ratings are surveys of what our community members think about DARA Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
DARA Biosciences (NASDAQ:DARA) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
DARA Biosciences (NASDAQ:DARA) Earnings History and Estimates Chart
DARA Biosciences (NASDAQ DARA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2015||Q3 2015||($0.14)||($0.14)||$0.83 million||$1.18 million||View||N/A|
|8/12/2015||Q215||($0.15)||($0.14)||$0.72 million||$0.99 million||View||Listen|
|5/13/2015||Q115||($0.12)||($0.16)||$0.75 million||$0.65 million||View||N/A|
|3/3/2015||Q4 2014||($0.11)||($0.04)||$0.75 million||$0.72 million||View||N/A|
|11/5/2014||Q3 2014||($0.13)||($0.11)||$0.55 million||$0.60 million||View||N/A|
|8/12/2014||Q114||($0.18)||($0.24)||$0.30 million||$0.41 million||View||N/A|
|5/12/2014||Q1 2014||($0.35)||($0.37)||$0.22 million||$0.16 million||View||N/A|
|2/4/2014||Q4 2013||($0.45)||($0.40)||$0.12 million||$0.18 million||View||N/A|
|11/14/2013||Q3 2013||($0.50)||($0.50)||$0.17 million||$0.14 million||View||N/A|
|8/14/2013||Q2 2013||($0.50)||($0.50)||$0.50 million||$0.08 million||View||N/A|
|5/15/2013||Q1 2013||($0.50)||($0.55)||$0.31 million||$0.02 million||View||N/A|
DARA Biosciences (NASDAQ:DARA) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for DARA Biosciences (NASDAQ:DARA)
No dividend announcements for this company have been tracked by MarketBeat.com
DARA Biosciences (NASDAQ DARA) Insider Trading and Institutional Ownership History
DARA Biosciences (NASDAQ DARA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/3/2013||Christopher G Clement||President||Buy||14,000||$0.71||$9,940.00|| |
|5/30/2013||Haywood D Cochrane||Director||Buy||10,000||$0.70||$7,000.00|| |
|5/23/2013||Timothy James Heady||Director||Buy||10,000||$0.75||$7,500.00|| |
|5/17/2013||David Drutz||CEO||Buy||25,000||$0.70||$17,500.00|| |
|9/17/2012||David Drutz||CEO||Buy||25,000||$1.06||$26,500.00|| |
|9/11/2012||Haywood D Cochrane||Director||Buy||5,000||$0.80||$4,000.00|| |
DARA Biosciences (NASDAQ DARA) News Headlines
|DARE Emboldened, IFRX On Track, APRI Awaits FDA Word, Watch Out For DYNT|
www.nasdaq.com - February 13 at 8:45 AM
|DARA Biosciences (DARA) & Its Peers Financial Review|
www.americanbankingnews.com - December 4 at 7:39 PM
|Head to Head Survey: Advanced Accelerator Application (AAAP) vs. DARA Biosciences (DARA)|
www.americanbankingnews.com - December 3 at 8:14 AM
|Head to Head Review: DARA Biosciences (DARA) vs. Its Competitors|
www.americanbankingnews.com - December 2 at 1:30 AM
|DARA Biosciences (DARA) versus The Competition Financial Survey|
www.americanbankingnews.com - December 1 at 9:24 PM
|Analyzing DARA Biosciences (DARA) & The Competition|
www.americanbankingnews.com - November 30 at 7:26 PM
|Reviewing DARA Biosciences (DARA) and Check-Cap (CHEK)|
www.americanbankingnews.com - November 30 at 5:28 PM
|Contrasting DARA Biosciences (DARA) & The Competition|
www.americanbankingnews.com - November 29 at 9:42 PM
|DARA Biosciences (DARA) versus The Competition Critical Survey|
www.americanbankingnews.com - November 27 at 11:26 AM
|DARA Biosciences (DARA) versus Its Peers Critical Contrast|
www.americanbankingnews.com - November 26 at 1:30 PM
|Financial Survey: AbbVie (ABBV) and DARA Biosciences (DARA)|
www.americanbankingnews.com - November 20 at 5:46 PM
|Financial Analysis: DARA Biosciences (DARA) and TherapeuticsMD (TXMD)|
www.americanbankingnews.com - November 19 at 11:34 AM
|Head to Head Comparison: DARA Biosciences (DARA) vs. Its Rivals|
www.americanbankingnews.com - November 15 at 1:38 PM
|Head to Head Review: DARA Biosciences (DARA) and Its Rivals|
www.americanbankingnews.com - November 14 at 5:18 AM
|Aimmune Therapeutics (AIMT) and DARA Biosciences (DARA) Head-To-Head Review|
www.americanbankingnews.com - November 6 at 9:28 PM
|Mallinckrodt PLC (MNK) versus DARA Biosciences (DARA) Head-To-Head Contrast|
www.americanbankingnews.com - November 5 at 5:54 PM
|Analyzing DARA Biosciences (DARA) & Its Rivals|
www.americanbankingnews.com - November 5 at 1:20 PM
|KNOW Bio strengthens leadership with the addition of four new Board Members|
www.bizjournals.com - October 24 at 8:10 PM
|DARA Biosciences (DARA) vs. Assembly Biosciences (ASMB) Financial Review|
www.americanbankingnews.com - October 4 at 2:36 PM
|Comparing DARA Biosciences (DARA) and Supernus Pharmaceuticals (SUPN)|
www.americanbankingnews.com - September 16 at 4:24 AM
|Analyzing Supernus Pharmaceuticals (SUPN) and DARA Biosciences (DARA)|
www.americanbankingnews.com - September 1 at 4:16 AM
|Scientists Take New Approach to Fighting Type 1 Diabetes|
www.wsj.com - June 25 at 3:02 AM
|Will microbes save agriculture? - Los Angeles Times|
www.latimes.com - May 28 at 4:06 PM
|Will Midatech Pharma plc be the next Shire plc? - Motley Fool UK|
www.fool.co.uk - May 4 at 4:08 PM
|Midatech Loss Widens On Acquisition Costs, But Revenue Surges - London South East (registration) (blog)|
www.lse.co.uk - April 13 at 4:14 PM
|Midatech Loss Widens On Acquisition Costs, But Revenue Surges|
www.morningstar.co.uk - April 13 at 4:14 PM
|MIDATECH PHARMA US INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting o|
biz.yahoo.com - December 4 at 5:07 PM
|DARA BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financi|
biz.yahoo.com - December 2 at 4:32 PM
|DARA BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan|
biz.yahoo.com - November 18 at 4:31 PM
|DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex|
biz.yahoo.com - November 2 at 4:36 PM
DARA Biosciences (NASDAQ:DARA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
DARA Biosciences (NASDAQ:DARA) Income Statement, Balance Sheet and Cash Flow Statement
DARA Biosciences (NASDAQ DARA) Stock Chart for Thursday, March, 22, 2018